ClinicalTrials.gg
RecruitingNCT07380698DOSTCONICGUpdated Feb 2, 2026

The Effect of Dose and Storage Conditions of Indocyanine Green on Efficacy and Cost in Sentinel Lymph Node Mapping in Gynecological Cancer

An observational study in Endometrial Cancer, Vulvar Cancers and Cervical Cancer, sponsored by Cukurova University. Recruiting at 1 site in Turkey (Türkiye). Open to female participants. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by Cukurova University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Endometrial Neoplasms with a site in Turkey — 14 open to participants now, 18 under way, 4 of them phase 3. Endometrial Neoplasms · Turkey.

Planned enrollment
11th of 13
30 · median 106
Started
2025
with 6 others
Observational
13 of 46
3 open now
Primary completion
2026-08
later than 6 of 17 live
Registered
42nd of 46
by date
Lead sponsor
2 of 46
Cukurova University

Among the 46 studies in Endometrial Neoplasms with a site in Turkey, this one is the 11th largest by planned enrollment of the 13 observational ones that give a count, is one of 7 that started in 2025, is one of 13 observational ones, reaches primary completion later than 6 of the 17 other live ones, and was the 42nd registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

14 of the 46 studies in Endometrial Neoplasms with a site in Turkey are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Endometrial Neoplasms with a site in Turkey, or all of them as a file.
02

Study summary

This research will determine the impact of optimizing dosage and storage conditions for indocyanine green on health outcomes and will contribute to improving treatment processes in gynecological cancers. Ultrastaging will increase the detection of micrometastases. Furthermore, the cost impact of these optimizations will be evaluated. It will help develop more effective, safe, and cost-effective methods for sentinel lymph node mapping in gynecological cancers. Furthermore, significant savings in healthcare costs could be achieved.

Read the detailed description

Indocyanine Green (ICG) is a substance used in many areas of medicine, particularly in surgical procedures for vascular imaging, organ function assessment, and the treatment of various types of cancer. In recent years, this substance has also gained significant ground in gynecological cancers. The use of indocyanine green in gynecological cancers is particularly notable for its role in identifying cancer cells, performing lymph node biopsies, and performing minimally invasive surgeries.

Indocyanine green has become an important tool in the treatment of gynecological cancers, particularly in lymph node biopsies and minimally invasive surgeries. Its applications are increasingly expanding as it helps identify the path of cancer spread and enhances surgical precision. This substance allows surgeons to perform more accurate and effective interventions while also accelerating patient recovery.

Sentinel lymph node (SLN) mapping is increasingly used in gynecologic cancers as a less morbid staging method, an alternative to systematic pelvic and para-aortic lymphadenectomy. Numerous prospective studies have demonstrated the accuracy and reliability of the SLN technique, particularly in endometrial, cervical, and vulvar cancers. Indocyanine green (ICG), when used in conjunction with near-infrared fluorescence imaging, has become the most frequently used method due to its high sensitivity and bilateral detection rate.Patients diagnosed with endometrial, cervical, and vulvar cancer and scheduled for SLN mapping will be included in the study; potential confounding variables such as patient characteristics (age, BMI, comorbidities), tumor characteristics (histology, stage), surgical approach, and surgeon experience will also be considered in the analyses. Indocyanine green administration in gynecological cancers:

  1. Standard dose (1.25 mg/mL, 4 x 1 mL)
  2. A low-volume protocol (1 mL) may be tried in low-risk cases for minimal intervention, but signal may be reduced.
  3. A high-volume application (8-10 mL) may be preferred in obese or signal-deficient patients; signal strength may be increased.
  4. A high concentration (2.5 mg/mL) has been found effective in some studies, but should be used with caution due to the risk of suppressing ICG's own fluorescence.

Standard storage conditions:

Storage at 2-8°C (refrigerated) in dark glass vials protected from light and moisture.

Short-term storage at room temperature (15-25°C) after preparation is suitable. Use within 24 hours is recommended. In this study, sentinel lymph node mapping will be performed by injecting 1 cc of indocyanine green diluted with sterile water (25 mg + 20 mL water → 1.25 mg/mL) into the submucosa of the cervical os at the 3-9 o'clock positions.

Prepared ICGs will be stored in a dark environment at +4°C.

The data obtained will evaluate the effects of the dosage on mapping success and also reveal the potential effects of indocyanine green storage conditions on efficacy and cost. This study aims to contribute to the development of a safer, more effective, and more economical mapping method for gynecological cancers.

Parameters used in this study:

  • Age (years)
  • BMI (kg/m²)
  • Parity
  • Comorbidities (DM, HT, cardiac/AKI, COPD, renal failure)
  • Drug/allergy history (especially iodine/ICG/green dye)
  • Previous pelvic surgery/lymph node dissection/RT-CT history
  • ASA score
  • Cancer type: endometrium, cervix, vulva
  • Cancer stage (clinical and/or pathological)
  • Histology (endometrioid/serous/clearcell/squamous, etc.)
  • Tumor size (mm), depth of myometrial invasion (%) in endometrial cancers, LVSI (present/absent), depth of stromal invasion in cervical tumors, parametrial involvement, lesion location and size in the vulva
  • Need for reinjection: Present/Absent
  • Injection sites and plan: 3-9 line (superficial/deep) on the cervix, clitoris level on the vulva, labia majora; cervical injection standardization for the endometrium. -Storage conditions
  • Freshly prepared vs. stored for a certain period
  • Temperature: Room temperature vs. Refrigerator
  • Operative: Laparoscopic/Laparotomic
  • Operative duration (min), time to SLN (min)
  • Intraoperative complications (allergic reaction, tissue staining problems, etc.)
  • Number of lymph nodes: Total SLNs removed, SLNs per side
  • Anatomical distribution: Obturator, external/internal iliac, parametrial, presacral, etc.
  • Micro/macrometastasis, isolated tumor cells
03

Conditions studied

  • Endometrial Cancer
  • Vulvar Cancers
  • Cervical Cancer
  • Indocyanine Green (ICG)

Keywords

  • endometrial cancer
  • vulvar cancers
  • cervical cancers
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women who have endometrial or cervical or vulvar cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • cervical cancer, endometrial cancer, vulvar cancer, using indocyanine green, sentinel lymph node dissection

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Target follow-up
1 Month
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Sentinel lymph node detection success rate associated with optimized indocyanine green (ICG) dosage and storage conditions.

    Time frame: Baseline (pre-procedure), perioperative/periprocedural period, and up to 24 weeks post-procedure.

Secondary outcomes

  1. Impact of optimizing indocyanine green (ICG) dosage and storage conditions on total procedural cost.

    Time frame: Baseline (pre-procedure) and up to 24 weeks post-procedure.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Bedynska M, Szewczyk G, Klepacka T, Sachadel K, Maciejewski T, Szukiewicz D, Fijalkowska A. Sentinel lymph node mapping using indocyanine green in patients with uterine and cervical neoplasms: restrictions of the method. Arch Gynecol Obstet. 2019 May;299(5):1373-1384. doi: 10.1007/s00404-019-05063-6. Epub 2019 Feb 14. PubMed 30762108 ↗
  • Laufer J, Scasso S, Papadia A. Impact of Indocyanine Green Dose on Sentinel Lymph Node Mapping in Cervical Cancer: A Systematic Review. Cancers (Basel). 2024 Sep 8;16(17):3107. doi: 10.3390/cancers16173107. PubMed 39272965 ↗
  • Cibula D, Potter R, Planchamp F, Avall-Lundqvist E, Fischerova D, Haie Meder C, Kohler C, Landoni F, Lax S, Lindegaard JC, Mahantshetty U, Mathevet P, McCluggage WG, McCormack M, Naik R, Nout R, Pignata S, Ponce J, Querleu D, Raspagliesi F, Rodolakis A, Tamussino K, Wimberger P, Raspollini MR. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer. Int J Gynecol Cancer. 2018 May;28(4):641-655. doi: 10.1097/IGC.0000000000001216. PubMed 29688967 ↗
  • Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, Campos SM, Chino J, Chon HS, Chu C, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Giuntoli R, Han E, Holmes J, Howitt BE, Lea J, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Podoll M, Salani R, Schorge J, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wethington SL, Wyse E, Zanotti K, McMillian NR, Aggarwal S. Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 Feb;21(2):181-209. doi: 10.6004/jnccn.2023.0006. PubMed 36791750 ↗

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Aug 2026, 10 months after the start.

Of 130 non-industry observational studies under Endometrial Neoplasms, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 206. This study's planned 10 months is below that.

Counting every sponsor, half of 150 studies reached it within 105 months; a quarter within 32 and three quarters within 206.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 1, 2026
First posted
Feb 2, 2026
StartActual
Oct 3, 2025
Primary completionEst.
Aug 3, 2026
CompletionEst.
Sep 3, 2026
Last update
Feb 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07380698
Responsible party
Ghanim Khatib (Associated Professor, Cukurova University) — Principal investigator
First posted
Feb 2, 2026
Start date
Oct 3, 2025
Primary completion
Aug 3, 2026 (estimated)
Completion
Sep 3, 2026 (estimated)
Last update
Feb 2, 2026

Study contacts

Ghanim Khatib, MD
Contact
ghanim.khatib@gmail.com
+903223386060

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion